Drug Price Watchdog Calls Bluebird Bio’s $2.1 Million Gene Therapy Cost-Effective – BioSpace
By daniellenierenberg
Courtesy of Pavlo Gonchar/SOPA Images/LightRocket via Getty Images
Drug pricing watchdog ICER, the Institute for Clinical and Economic Review, issued a draft report on bluebird bios gene therapy betibeglogene autotemcel for beta-thalassemia. Despite the proposed price tag of $2.1 million, ICERs not-yet-finalized report supports the therapys cost-effectiveness. This is good news for the recently beleaguered company.
Gene therapies are typically designed to cure a disease by replacing or fixing a damaged gene. Bluebirds therapy, which is listed under the brand name Zynteglo, had been approved in Europe and the UK, where its price is around $1.7 million (U.S.). However, the company pulled the therapy off the market in Europe over what it called a hostile pricing and reimbursement environment.
On April 5, bluebird bio announced it was beginning a comprehensive restructuring in hopes of cutting $160 million in costs over the next two years. It planned to re-focus on near-term catalysts, which include Zynteglo in the U.S., gene therapy for cerebral adrenoleukodystrophy (eli-cel) and a potential biologics license application (BLA) for lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease. The BLA application is planned for 2023, while the U.S. regulatory decisions are expected this year. The PDUFA date for Zynteglo is Aug.19, 2022, and Sept. 16, 2022, for eli-cel.
As part of the restructuring, the company is cutting its workforce by about 30%.
ICER recommendations arent binding, but they have influence. If ICER says a drug is overpriced, it provides ammunition for payers, such as Medicare and insurers, to push back against proposed prices.
Gene therapies are very expensive. For example,Novartis Zolgensma, the one-time gene therapy onasemnogene abeparvovec for spinal muscular atrophy (SMA), is generally viewed as the most expensive drug with a price tag of $2.1 million. On the other hand, as an apparent cure for a disease that kills children by the age of two, it is very rare. The argument for these therapies, aside from their curative potential for otherwise incurable diseases, is that over the life of the patient, they are cost-effective.
Novartis and Spark Therapeuticss gene therapy Luxturna (voretigene neparvovec) runs about $850,000 per patient in the U.S. The therapy is for inherited retinal dystrophy with RPE65 mutations. It is typically diagnosed in childhood and eventually causes almost total blindness, and the therapy is essentially a cure.
Beta thalassemia is a genetic disease that impairs the ability of red blood cells to manufacture hemoglobin, the molecule in the body that carries oxygen. There are about 40,000 newly diagnosed cases in children each year around the world. People with the most severe form of it develop life-threatening anemia around four to six months of age and have to receive monthly blood transfusions and other treatments, such as iron-chelating drugs. The only other potential cure is hematopoietic stem cell transplantation (HSCT) but requires a donor with a matching human leukocyte antigen (HLA) profile within the appropriate age range.
Bluebirds Zynteglo appears to be another option for a cure, although how long the therapys effects last is something of an open question. The ICER report noted the uncertainties, but concluded that the evidence suggests that beti-cel provides net health benefits to patients with TDT.
The ICER report indicated, per Managed Healthcare Executive, that "patients could be treated without reaching the potential budget impact threshold at three prices (about $1.85 million, $2.11 million and $2.38 million per course of treatment). This analysis was done at several prices to document the percentage of patients who could be treated without crossing a potential budget impact threshold that is aligned with the overall growth in the U.S. economy.
In Phase III trials, 89% of patients who received the therapy became transfusion independent, and in Phase I/II and III trials, those patients remained transfusion-free for at least 42 months. In general, side effects were mild and no deaths were reported. In December 2021, bluebird presented data at the American Society of Hematology meeting from a long-term study (LTF-303) that showed adult and pediatric patients with beta-thalassemia who required regular red blood cell transfusions can produce normal or near-normal levels of total hemoglobin and remain transfusion-free with stable iron markers up to seven years after receiving beti-cel.
A 2017 study published in Blood found that on average, beta-thalassemia patients required 17 transfusions per year, 23 days apart. Mean total healthcare costs for the patients were $128,062, plus or minus $62,260 per year. Total costs were primarily driven by chelation and transfusion costs.
Although the severity of the disease varies, a 2009 study found that people with beta-thalassemia major often die from cardiac complications of iron overload by 30 years of age," making bluebird's new therapy, if it is successful, vital for these patients.
View post:
Drug Price Watchdog Calls Bluebird Bio's $2.1 Million Gene Therapy Cost-Effective - BioSpace
- UMass Amherst Engineers Create Bioelectronic Mesh Capable of Growing with Cardiac Tissues for Comprehensive ... - Diagnostic and Interventional... - March 26th, 2024
- Stressing heart cells to study disease - AIP.ORG - American Institute of Physics - March 18th, 2024
- 'Heart-on-a-chip' to test chemotherapies and other cancer drugs for heart toxicity - Medical Xpress - February 7th, 2024
- Treating and preventing abnormal heart beats with stem cell muscle grafts - Medical Xpress - February 7th, 2024
- Stem Cell Therapy Boosts Quality of Life for People With Advanced Heart Failure - MedicineNet - December 20th, 2023
- Regenerative medicine can be a boon for those with Drug-Resistant Tuberculosis - Hindustan Times - April 21st, 2023
- Cardiac stem cells: Current knowledge and future prospects - April 13th, 2023
- Stem cell therapies in cardiac diseases: Current status and future ... - April 13th, 2023
- Stem Cell and Regenerative Biology | Johns Hopkins Heart and Vascular ... - April 13th, 2023
- Center for Regenerative Biotherapeutics - Cardiac Regeneration - April 13th, 2023
- MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com - March 25th, 2023
- CAREDX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com - March 1st, 2023
- A Possible Connection between Mild Allergic Airway Responses and Cardiovascular Risk Featured in Toxicological Sciences - Newswise - February 4th, 2023
- Baby's life saved by surgeon who carried out world's first surgery ... - December 25th, 2022
- An organoid model of colorectal circulating tumor cells with stem cell ... - December 25th, 2022
- Skeletal Muscle Cell Induction from Pluripotent Stem Cells - December 1st, 2022
- Stem-cell niche - Wikipedia - December 1st, 2022
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 13th, 2022
- Global Induced Pluripotent Stem Cell ((iPSC) Market to Reach $0 Thousand by 2027 - Yahoo Finance - October 13th, 2022
- Scientists Spliced Human Brain Tissue Into The Brains of Baby Rats - ScienceAlert - October 13th, 2022
- Decoding the transcriptome of calcified atherosclerotic plaque at single-cell resolution | Communications Biology - Nature.com - October 13th, 2022
- Global Synthetic Stem Cells Market Is Expected To Reach Around USD 42 Million By 2025 - openPR - October 13th, 2022
- Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine -... - October 13th, 2022
- Regenerative Medicine For Heart Diseases: How It Is Better Than Conventional Treatments | TheHealthSite.co - TheHealthSite - October 5th, 2022
- 'Love hormone' oxytocin could help reverse damage from heart attacks via cell regeneration - Study Finds - October 5th, 2022
- Recapitulating Inflammation: How to Use the Colon Intestine-Chip to Study Complex Mechanisms of IBD - Pharmaceutical Executive - September 27th, 2022
- Adult Stem Cells // Center for Stem Cells and Regenerative Medicine ... - September 19th, 2022
- CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease - Cardiovascular Diabetology - Cardiovascular... - September 19th, 2022
- Kite's CAR T-cell Therapy Yescarta First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and... - September 19th, 2022
- Neural crest - Wikipedia - September 3rd, 2022
- Rise In Number Of CROS In Various Regions Such As Europe Is Expected To Fuel The Growth Of Induced Pluripotent Stem Cell Market At An Impressive CAGR... - September 3rd, 2022
- Discover the Mental and Physical Health Benefits of Fasting - Intelligent Living - September 3rd, 2022
- Heart Association fellowship to support research - Binghamton - August 26th, 2022
- Repeated intravenous administration of hiPSC-MSCs enhance the efficacy of cell-based therapy in tissue regeneration | Communications Biology -... - August 26th, 2022
- High intensity interval training protects the heart against acute myocardial infarction through SDF-1a, CXCR4 receptors and c-kit levels - Newswise - August 26th, 2022
- Yale University: Uncovering New Approaches to a Common Inherited Heart Disorder | India Education - India Education Diary - August 10th, 2022
- Heart failure in obesity: insights from proteomics in patients treated with or without weight-loss surgery | International Journal of Obesity -... - August 10th, 2022
- Pigs died after heart attacks. Scientists brought their cells back to life. - Popular Science - August 10th, 2022
- Protocol for a Nested, Retrospective Study of the Australian Placental Transfusion Study Cohort - Cureus - August 10th, 2022
- Autologous Cell Therapy Market Size to Grow by USD 4.11 billion, Bayer AG and Brainstorm Cell Therapeutics Inc. Among Key Vendors - Technavio - PR... - August 2nd, 2022
- UTSW researcher part of team awarded $36 million heart research grant - The Dallas Morning News - August 2nd, 2022
- Buffalo center fuels research that can save your life from heart disease and stroke - Buffalo News - August 2nd, 2022
- Hyperglycaemia-Induced Impairment of the Autorhythmicity and Gap Junction Activity of Mouse Embryonic Stem Cell-Derived Cardiomyocyte-Like Cells -... - July 25th, 2022
- NASA's Solution to Stem Cell Production is Out of this World - BioSpace - July 25th, 2022
- Inhibition of pancreatic EZH2 restores progenitor insulin in T1D donor | Signal Transduction and Targeted Therapy - Nature.com - July 25th, 2022
- 'My Teen Sweetheart And I Drifted Apart. 30 Years Later I Made a Shocking Discovery' - Newsweek - July 25th, 2022
- EU: New Blood? Proposed Revisions to the EUs Blood, Tissues and Cells Rules - GlobalComplianceNews - July 25th, 2022
- Stem Cells Market to Expand at a CAGR of 10.4% from 2021 to 2028 Travel Adventure Cinema - Travel Adventure Cinema - July 25th, 2022
- Cell Separation Technologies Market Expands with Rise in Prevalence of Chronic Diseases, States TMR Study - GlobeNewswire - July 25th, 2022
- Dental Membrane and Bone Graft Substitutes Market to Exceed Value of US$ 1,337 Mn by 2031 - PR Newswire UK - July 25th, 2022
- Stem Cells Used to Repair Heart Defects in Children - NBC 5 Dallas-Fort Worth - July 16th, 2022
- Pneumonia and Heart Disease: What You Should Know - Healthline - July 16th, 2022
- Promising solution to fatal genetic-disorder complications discovered by University professor and Ph.D. candidate - Nevada Today - July 16th, 2022
- Current and advanced therapies for chronic wound infection - The Pharmaceutical Journal - July 16th, 2022
- Why do some women struggle to breastfeed? A UCSC researcher on what we know, and don't - Lookout Santa Cruz - July 16th, 2022
- Mesenchymal stem cells: from roots to boost - PMC - July 8th, 2022
- New study allows researchers to more efficiently form human heart cells from stem cells - University of Wisconsin-Madison - July 8th, 2022
- Dr Victor Chang saved hundreds of lives. 31 years ago today, he was murdered. - Mamamia - July 8th, 2022
- Exosome Therapeutics Market Research Report Size, Share, New Trends and Opportunity, Competitive Analysis and Future Forecast Designer Women -... - July 8th, 2022
- Cell Line Development Market: Increase in Prevalence of Cancer and Other Chronic Diseases to Drive the Market - BioSpace - July 8th, 2022
- Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and... - July 8th, 2022
- What New Advances are there in 3D Bioprinting Tissues? - AZoM - June 30th, 2022
- Technical Advancements & Innovative Products Likely to Expand Application of Surgical Meshes in Untapped Domains, States Fact.MR - BioSpace - June 30th, 2022
- Liso-cel Approval Provides Earlier, Expanded Access to CAR T-cell Therapy in Second-line LBCL - OncLive - June 30th, 2022
- Stem cells, embryos, and the environment: a context for both science ... - June 20th, 2022
- Getting to the heart of engineering a heart - Harvard School of Engineering and Applied Sciences - June 11th, 2022
- 'Ghost heart': Built from the scaffolding of a pig and the patient's cells, this cardiac breakthrough may soon be ready for transplant into humans -... - June 11th, 2022
- Current and Future Innovations in Stem Cell Technologies - Labmate Online - June 11th, 2022
- Bioabsorbable Stents Market to Grow at a Fine CAGR of 9.6% through 2032: Improvements in Healthcare Infrastructure and Growing Geriatric Population to... - June 11th, 2022
- Is a Bioengineered Heart From Recipient Tissues the Answer to the Shortage of Donors in Heart Transplantation? - Cureus - May 29th, 2022
- Global Heart Failure Pipeline Market Research Report 2022: Comprehensive Insights About 90+ Companies and 90+ Pipeline Drugs - ResearchAndMarkets.com... - May 29th, 2022
- Whats a heart attack? How can you tell if youre on the edge of one? - Sydney Morning Herald - May 29th, 2022
- Heart, cancer and diabetes projects among winners of funding boost for stem cell therapies - The Globe and Mail - May 13th, 2022
- Meet the Canadian researcher determined to take the animals out of lab testing - CBC.ca - May 13th, 2022
- Stem cell-based regenerative medicine - PMC - April 29th, 2022
- Global Stem Cell Market To Be Driven By Increasing Activities To Use Stem Cells In Regenerative Medicines In The Forecast Period Of 2022-2027 ... - April 29th, 2022
- Montefiore Einstein Cancer Center Finds CAR-T Therapy Effective in Black and Hispanic Patients - Newswise - April 29th, 2022
- Global, regional, and national burden of hypertensive heart disease during 19902019: an analysis of the global burden of disease study 2019 - BMC... - April 29th, 2022
- First all-private astronaut team aboard space station heads for splashdown - KFGO - April 29th, 2022
- James Woody, CEO of 180 Life Sciences: Developing New Therapies to Treat Inflammatory Diseases - DocWire News - April 29th, 2022